Company profile: Azeria Therapeutics
1.1 - Company Overview
Company description
- Provider of small-molecule cancer drug development, creating a pipeline of therapies designed to selectively inhibit pioneer factors to aid treatment of breast and prostate cancer patients.
Products and services
🔒
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Azeria Therapeutics
Kura Oncology
HQ: United States
Website
- Description: Provider of precision medicines for solid tumors and blood cancers, advancing investigational therapies including ziftomenib for AML with specific mutations, tipifarnib for HRAS-mutant head and neck squamous cell carcinoma and other cancers, and KO-2806, a next-generation FTI for advanced solid tumors; also conducts clinical trials and offers expanded access programs.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Kura Oncology company profile →
Provectus Biopharmaceuticals
HQ: United States
Website
- Description: Provider of investigational therapies for skin, liver, and breast cancers and dermatological conditions, including PV-10, an intratumoral immunotherapy using rose bengal disodium for solid tumors such as melanoma, and PH-10, a topical rose bengal disodium formulation under study.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Provectus Biopharmaceuticals company profile →
Vor Bio
HQ: United States
Website
- Description: Provider of immuno-oncology therapies for AML, including VOR33, a gene-edited hematopoietic stem cell therapy lacking CD33 to shield healthy blood cells from targeted therapies, and VCAR33ALLO, an allogeneic anti-CD33 CAR-T for relapsed or refractory post-transplant AML. Runs clinical trials (VBP101, VBP301) and collaborates with blood cancer advocacy groups to support the AML patient community.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Vor Bio company profile →
MetaStat
HQ: United States
Website
- Description: Provider of diagnostic technologies and therapeutics for the early detection and treatment of systemic metastasis.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full MetaStat company profile →
Tilos Therapeutics
HQ: United States
Website
- Description: Provider of antibody therapeutics targeting key immunological pathways, with a focus on regulatory T cells and effector cell regulation; developing anti-LAP antibodies specific to the Latency Associated Peptide of TGF beta for cancer treatment. Founded in 2016 and based in Cambridge, Massachusetts.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Tilos Therapeutics company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Azeria Therapeutics
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Azeria Therapeutics
2.2 - Growth funds investing in similar companies to Azeria Therapeutics
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Azeria Therapeutics
4.2 - Public trading comparable groups for Azeria Therapeutics
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →